A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug being developed for the trea

Trial Details

NCT ID
NCT05650632
Phase
PHASE1
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Etentamig (ABBV-383)
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Springdale, Arkansas, United States|36.18674,-94.12881
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Newark, Delaware, United States|39.68372,-75.74966
  • Hinsdale, Illinois, United States|41.80086,-87.93701

Key Eligibility Criteria

  • Must have measurable disease as outlined in the protocol.
  • Eastern Cooperative Oncology Group (ECOG) performance of \<= 2. Arm C and Arm D: ECOG performance of \<= 1.
  • Relapsed/refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen ba…
  • Must be naïve to treatment with etentamig (ABBV-383).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →